KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

Krystal Biotech, Inc. (KRYS) has disclosed a new risk, in the Demand category. Krystal Biotech, Inc. faces significant risks related to scaling ...

Krystal Biotech Inc (KRYS) reports impressive Q3 2024 results with significant VYJUVEK revenue growth and strategic plans for ...

November 4, 2024Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023JNDA for B-VEC filed and on track for commercial ...

基因疗法公司Krystal Biotech Inc. (NASDAQ: KRYS)宣布2024年第三季度实现盈利，每股收益显著增加，其主打产品VYJUVEK的收入大幅增长。在2024年11月1日的业绩电话会议上，公司概述了其成功的商业策略，包括高度关注患者和医生体验，这推动了需求和报销审批。Krystal Biotech还讨论了其临床管线的进展，并提供了在欧洲和日本扩张计划的最新情况。 要点摘要 ...

What gives this company further value is that it has already received FDA approval of a topical gel drug known as VYJUVEK. It was approved to treat wounds in patients 6 months of age and older ...

周一，花旗将Krystal生物科技(NASDAQ:KRYS)的目标股价从之前的$204.00上调至$206.00。尽管如此，花旗仍维持中性评级。这一调整是在评估Krystal生物科技的销售和管理层指引后做出的。 Krystal生物科技报告其基因疗法产品Vyjuvek的销售额为$83.8百万，与花旗预估的$82.3百万和市场共识的$83.4百万基本一致。然而，花旗注意到一些令人担忧的问题，特别是患者 ...

MONROE, Ohio, May 22, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is ...